To demonstrate the real-world impact of these expanded capabilities, Tempus will showcase a landmark study at ASCO 2026, describing clinically meaningful improvements in rates of biomarker testing for ...

Tempus AI Inc TEM stock is trading higher on Thursday morning following a key product expansion announcement. The company ...

In recent days, Tempus AI announced a string of oncology-focused product advances, including FDA approval of its xT CDx tumor-only sequencing assay, major upgrades to its AI-enabled Next and Hub ...

Tempus AI has an immunology risk testing product ready for researchers to test out and is working with Cleveland Clinic on better ways to assess how immunotherapy might work on patients. The ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for ...

The ArteraAI Prostate Test (mHSPC) is the first externally developed digital pathology algorithm being made clinically available through the Tempus ecosystem. This AI-powered test assesses a patient's ...

Tempus AI’s TEM strategic focus for 2026 centers on expanding its AI-driven precision medicine platform by scaling the ...

Tempus AI’s latest analyst update keeps the fair value target unchanged at US$67.20 per share, even as model assumptions are fine tuned. The steady target sits against a mixed backdrop, where some ...

Tempus AI is expanding its clinical oncology offering with the launch of ArteraAI Prostate Test for metastatic hormone-sensitive prostate cancer. ・The tool combines digital pathology and genomic ...

Tempus AI Inc. (NASDAQ:TEM) is one of the 9 Stocks Stealing the Show. Tempus AI extended its winning streak to a 3rd straight session on Wednesday, surging 13.89 percent to close at $56.41 apiece, as ...

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of the ...

Tempus announced this morning it has inked agreements for in-network provider status with Blue Cross Blue Shield health plans in six states, significantly enhancing its relationships with commercial ...